Circulating microparticles as indicators of peripartum cardiomyopathy

European Heart Journal

Volumn 33, Issue 12, 2012, Pages 1469-1479

  Walenta, Katrin ^a   Schwarz, Viktoria ^a   Schirmer, Stephan H ^a   Kindermann, Ingrid ^a   Friedrich, Erik B ^a   Solomayer, Erich Franz ^b   Sliwa, Karen ^c   Labidi, Saida ^d   Hilfiker Kleiner, Denise ^d   Bhm, Michael ^a  

^a Klinik fur Innere Medizin III   (Germany)

^b Geburtshilfe und Reproduktionsmedizin   (Germany)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Heart failure; Microparticles; Peripartum cardiomyopathy; Vascular damage

Indexed keywords

BIOLOGICAL MARKER; BROMOCRIPTINE; ENALAPRIL; FUROSEMIDE;

ADULT; ARTICLE; CLINICAL INDICATOR; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; ENDOTHELIAL MICROPARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; ISCHEMIC CARDIOMYOPATHY; LEUKOCYTE MICROPARTICLE; MAJOR CLINICAL STUDY; MEMBRANE MICROPARTICLE; MONOCYTE MICROPARTICLE; PERIPARTUM CARDIOMYOPATHY; PLATELET MICROPARTICLE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BROMOCRIPTINE; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; FEMALE; FLOW CYTOMETRY; HORMONE ANTAGONISTS; HUMANS; PREGNANCY; PUERPERAL DISORDERS;

EID: 84861093373     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr485     Document Type: Article

References (46)

1. Mielniczuk LM, Williams K, Davis DR, Tang AS, Lemery R, Green MS, Gollob MH, Haddad H, Birnie DH. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006;97:1765-1768. (Pubitemid 43817868)
2. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995;25:118-123.
3. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005;80:1602-1606. (Pubitemid 41747062)
4. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589-600. (Pubitemid 46206082)
5. Hilfiker-Kleiner D, Knoll R. Disease-modifying mutations in familial hypertrophic cardiomyopathy: complexity from simplicity. Circulation 2008;117:1775-1777. (Pubitemid 351507465)
6. Hilfiker-Kleiner D, Meyer GP, Schieffer E, Goldmann B, Podewski E, Struman I, Fischer P, Drexler H. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007;50: 2354-2355. (Pubitemid 350192108)
7. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, McMurray J, Yamac H, Labidi S, Struhman I, Hilfiker-Kleiner D. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010;121:1465-1473.
8. Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol 2007;137:36-38.
9. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res 2009;335:143-151.
10. Jimenez J, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003;109:175-180. (Pubitemid 36712905)
11. Ó Connor C, Gurbel P, Serebruany V. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999;83:1345-1349. (Pubitemid 29205744)
12. Yin W, Chen J, Jen HL, Chiang MC, Huang WP, Feng AN, Lin SJ, Young MS. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail 2003;5:507-519.
13. Chong A, Blann A, Lip G. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. Q J Med 2003;96:253-267. (Pubitemid 36432385)
14. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011;31:27-33.
15. Leroyer AS, Anfosso F, Lacroix R, Sabatier F, Simoncini S, Njock SM, Jourde N, Brunet P, Camoin-Jau L, Sampol J, Dignat-George F. Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost 2010;104:456-463.
16. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, Sumida H, Matsui K, Jinnouchi H, Ogawa H. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009;54: 601-608.
17. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999;30:111-142. (Pubitemid 29232249)
18. Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, Horstman LL, Soriano AO, Zambrano JP, Ahn YS. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005;45:1467-1471. (Pubitemid 40615620)
19. VanWijk MJ, Kublickiene K, Boer K, VanBavel E. Vascular function in preeclampsia. Cardiovasc Res 2000;47:38-48. (Pubitemid 30408548)
20. Meziani F, Tesse A, David E, Martinez MC, Wangesteen R, Schneider F, Andriantsitohaina R. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol 2006; 169:1473-1483. (Pubitemid 351194378)
21. Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011;105:396-408.
22. Weber H, Kollars M, Kyrle PA. Comparison of different methods for isolation and storage of microparticles from human blood. J Thromb Haemost 2007;5(Suppl. 2): P-M-445.
23. Dey-Hazra E, Hertel B, Kirsch T, Woywodt A, Lovric S, Haller H, Haubitz M, Erdbruegger U. Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag 2010;6:1125-1133.
24. Van Ierssel SH, Van Craenenbroeck EM, Conraads VM, Van Tendeloo VF, Vrints CJ, Jorens PG, Hoymans VY. Flow cytometric detection of endothelial microparticles (EMP): Effects of centrifugation and storage alter with the phenotype studied. Thromb Res 2010;125:332-339.
25. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, van Veldhuisen DJ, Watkins H, Shah AJ, Seferovic PM, Elkayam U, Pankuweit S, Papp Z, Mouquet F, McMurray JJ. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12:767-778.
26. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A. Pregnancy-associated cardiomyopathy: Clinical characteristics and a comparison between early and late presentation. Circulation 2005;111:2050-2055. (Pubitemid 40577899)
27. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation 1971;44: 964-968.
28. Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. J Obstet Gynecol 1999;94: 311-316. (Pubitemid 29352883)
29. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, Ansari A, Baughman KL. Peripartum Cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institute of Health) workshop recommendations and review. JAMA 2000;283:1183-1188. (Pubitemid 30126607)
30. Rizeq M, Rickenbacher P, Fowler M, Billingham M. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 1994;74:474-477. (Pubitemid 24269967)
31. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, van der Werf R, Jongbloed JD, Paulus WJ, Dooijes D, van den Berg MP. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010; 121:2169-2175.
32. Morales A, Painter T, Li R, Siegfried JD, Li D, Norton N, Hershberger RE. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 2010;121:2176-2182.
33. Anderson J, Horne B. Birthing the genetics of peripartum cardiomyopathy. Circulation 2010;121:2157-2159.
34. Elkayam U, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. Circulation 2010;121:1463-1464.
35. Jahns B, Stein W, Hilfiker-Kleiner D, Pieske B, Emons G. Peripartum cardiomyopathy: A new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol 2008;199:e5-e6.
36. Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, Stewart S. Spectrum of heart disease and risk factors in a black urban population in South Africa (the heart of Soweto study): A cohort study. Lancet 2008;371: 915-922. (Pubitemid 351375275)
37. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006;368:687-693. (Pubitemid 44223695)
38. Sliwa K, Fö rster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006;27:441-446. (Pubitemid 43209169)
39. Sakariassen KS, Holme PA, Orvim U, Barstad RM, Solum NO, Brosstad FR. Shearinduced platelet activation and platelet microparticle formation in native human blood. Thromb Res 1998;92:S33-S41. (Pubitemid 29012761)
40. Canault M, Leroyer AS, Peiretti F, Lesèche G, Tedgui A, Bonardo B, Alessi MC, Boulanger CM, Nalbone G. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-(alpha) converting enzyme/ ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 2007;171:1713-1723. (Pubitemid 350158331)
41. Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles in atherothrombosis. J Intern Med 2008;263:528-537. (Pubitemid 351533557)
42. Mezentsev A, Merks RM, O'Riordan E, Chen J, Mendelev N, Goligorsky MS, Brodsky SV. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol 2005;289:H1106-H1114. (Pubitemid 41208953)
43. Pfister SL. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery. Hypertension 2004;43:428-433. (Pubitemid 38174150)
44. Werner N, Kosiol S, Schiegl T, Ahlers P,Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007. (Pubitemid 41262334)
45. Sinning JM, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2010; doi:10.1093/eurheartj/ehq478.
46. A Endorsed by the European Society of Gynecology (ESG), the Association for European Paediatric Cardiology (AEPC), and the German Society for Gender Medicine (DGesGM); Authors/Task Force Members, Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L; ESC Committee for Practice Guidelines (CPG), Bax J, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Baumgartner H, Deaton C, Aguiar C, Al-Attar N, Garcia AA, Antoniou A, Coman I, Elkayam U, Gomez-Sanchez MA, Gotcheva N, Hilfiker-Kleiner D, Kiss RG, Kitsiou A, Konings KT, Lip GY, Manolis A, Mebaaza A, Mintale I, Morice MC, Mulder BJ, Pasquet A, Price S, Priori SG, Salvador MJ, Shotan A, Silversides CK, Skouby SO, Stein JI, Tornos P, Vejlstrup N, Walker F, Warnes C. ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; doi:10.1093/ eurheartj/ ehr218.